CV6 to Present Details of Ongoing Phase 1a Clinical Trial at 2024 ASCO Annual Meeting

13th May 2024 10:42 am

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK, 10 May 2024 – CV6 Therapeutics (‘CV6’) is a clinical-stage drug development company targeting Uracil-DNA biology to transform the treatment of cancer and inflammatory diseases. CV6 will be presenting details of their ongoing CV6-168 Phase 1a clinical trial at the 2024 ASCO Annual Meeting to be held at McCormick Pace in Chicago, USA on […]

CV6 Therapeutics Featured in the NI Edition of the 12 Clusters of Tech

5th January 2021 12:00 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK. 5th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases,  have been featured in the November 2020 special report on the ‘12 Clusters of Tech’, a national campaign to champion leading clusters of UK technology led by the UK Tech Cluster […]

CV6 Therapeutics Inc Recognised as a Platinum Level Innovator

4th January 2021 1:12 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK. 4th January, 2021. CV6 Therapeutics, a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that they have been recognised as a Platinum Level Innovator by Innovate Northern Ireland on behalf of the Department of the Economy for Northern Ireland. The award was based […]

CV6 CEO Invited to Participate in Leading Biotech Europe CEO Event

15th March 2019 10:04 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK. 15th March, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that CEO and Founder Dr Robert Ladner has been invited to participate in the Europe CEO networking forum in Vienna, Austria on the 24th of March, 2019. Europe CEO is […]

CV6 CEO to Present at Biotech Showcase™ 2019 in San Francisco

7th January 2019 2:09 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK. 7th January, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that it will be featured as a presenting company at Biotech Showcase™ 2019, to be held on the 7th-9th January at the Hilton San Francisco Union Square. […]

CV6 to Present Details of CV6-168 at Molecular Targets and Cancer Therapeutics Symposium  

25th September 2018 1:49 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK. 25 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, today announced they would be presenting details on CV6-168, a novel anticancer therapeutic at the 30th EORTC/AACR/NCI Molecular Targets and Cancer Therapeutics Symposium in Dublin, Ireland on 16th of November 2018. The abstract […]

CV6 CEO Presents at Prestigious Heidelberger Symposium on Cancer Research

18th September 2018 2:25 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, U.K. – 18 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, announced today that Dr. Robert Ladner, CEO and Founder, was invited to present the Company’s ground-breaking research that led to the development of the novel dUTPase inhibitor and clinical drug […]

CV6 CEO Speaks at Patrick Johnston QUB Memorial Symposium

18th May 2018 11:33 am

Posted by cv6-admin

CV6 Therapeutics

Belfast, UK. 17 May, 2018. Robert Ladner, CEO and Founder of CV6 Therapeutics Ltd (CV6), paid tribute today to Professor Patrick G. Johnston at a memorial symposium hosted by Queen’s University Belfast to honour and celebrate the life and accomplishments of “A Leader and Innovator in Cancer Research and Treatment”. Patrick, or ‘Paddy’ to those who […]

CV6 Therapeutics Strengthens Scientific Advisory Board with Recent Appointments

17th May 2018 1:24 pm

Posted by cv6-admin

CV6 Therapeutics

Belfast, U.K. – May 17, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of two new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, UK. […]